ArticleResearch and practice in thrombosis and haemostasis2026
Evaluation of 3 commercial assays for the measurement of tissue factor activity in human plasma.
Article in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Background: Levels of tissue factor (TF)-positive extracellular vesicles (EVs) are increased in plasma from patients with different diseases. However, the low TF levels in plasma are difficult to measure due to the presence of TF pathway inhibitor and the low sensitivity of assays. Objectives: We evaluated the ability of 3 commercial kits to measure TF activity levels in human plasma. Methods: We used the Abcam, AssaySense, and Actichrome colorimetric assay kits to measure recombinant TF (Innovin) and procoagulant activity (PCA) in plasma from lipopolysaccharide (LPS)-stimulated human whole blood from 4 healthy donors. We used different anticoagulants and plasma preparations according to the recommendations of the different kits. We examined the effects of depleting EVs and adding an anti-TF antibody on PCA. The Chapel Hill EV TF activity assay was used for comparison. Results: All 3 kits detected Innovin. The commercial kits detected higher PCA levels in some LPS treated samples but not others compared to controls Higher PCA levels were detected with the Abcam and AssaySense kits compared with the Actichrome kit. Depletion of EVs abolished PCA in both control and LPS plasmas. The Abcam and AssaySense kits detected TF-dependent PCA in LPS samples, but with lower sensitivity compared with the Chapel Hill assay. Conclusion: In this study, we found that the Abcam and AssaySense kits detected TF-dependent PCA in human plasma. However, these assays had lower sensitivity and specificity compared with the Chapel Hill EV TF activity assay.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.